Skip to main content
. 2020 Jan 16;9(1):224. doi: 10.3390/cells9010224

Figure 1.

Figure 1

Exploiting EV characteristics to enhance or evade immune response (A) Engineered EVs stimulate immune cell infiltration into tumors and disease regression (B) CD47+ve EVs evade host immunity resulting in increased persistence and improved therapeutic response. (DEV-AFP: Dendritic EV α-fetaprotein; HSP: Heat Shock Protein; IL: Interleukin; IFN: Interferon. (Image created using Biorender.com—paid subscription).